Keytruda ( Pembrolizumab ) has demonstrated superior progression-free and overall survival compared to chemotherapy in patients whose tumors expressed high levels of PD-L1.
FDA ( Food and Drug Administration ) has also approved a labeling update for Keytruda for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 ( TPS of 1% or more ) with disease progression on or after Platinum-containing chemotherapy; patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda.
According to Roy S. Herbst at Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven, with this new indication, Keytruda can now be a first treatment option instead of chemotherapy for patients with metastatic non-small cell lung cancer whose tumors express high levels of PD-L1. These data reaffirm the importance of testing for PD-L1 expression in non-small cell lung cancer in order to identify those patients who are most likely to benefit from treatment with Keytruda.
Please contact us in case you should be in need of this pharma product. We can ship this product under refrigeration in any part of the world in 72/96 hours.